Bilirubin Measurement

to diagnose hyperbilirubinemia

Prevention/Diagnostic
Diagnostic/Prevention
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT
  • OVERVIEW
  • TECHNOLOGY Characteristics
  • Bilirubin Measurement
    Representative Product

    Hyperbilirubinemia, an infrequent cause of mortality during the first month of life, is a major cause of preventable neonatal morbidity.

    Condition
    Neonatal hyperbilirubinemia (severe jaundice) is a common condition in newborns caused by elevated concentration of bilirubin, a neurotoxin.

    Mechanism of Action
    Analysis of blood serum, transcutaneous measurement, and clinical (visual inspection) are all possible methods for hyperbilirubinemia diagnosis. The gold standard method for bilirubin measurement is high performance liquid chromatography used on blood serum, but this method is only used in research laboratories. Medical laboratories can measure the bilirubin of blood by measuring light passed through a sample. Alternatively, these labs might be done chemically.

     

    At the point of care, transcutaneous devices enable noninvasive measurement throughe skin. These devices measure skin reflectance, but they have limited sensitivity and specificity. Clinical diagnosis of jaundice is possible based on yellow pigmentation of the skin, however, even with a reference color strip, visual assessment is the least sensitive method.


    Current use in High-Resource Settings
    Blood gas analyzers or chemistry analyzers, such as the Beckman Coulter AU480 are most common in well-resourced settings. These devices have a throughput of hundreds of samples per hour and can perform dozens of other tests in addition to bilirubin concentration.

    Application in Low-Resource Settings
    Microcapillary photometric devices dedicated solely to bilirubin measurement, such as the Ginevri One Beam, offer relatively accurate bilirubin measurement and are compact and easy to use. Though the capital cost of these devices is much less than most blood gas or chemistry analyzers, cost is still a barrier to widespread adoption. Transcutaneous devices have a similar capital cost and offer two significant advantages for low-resource settings: the non-invasive measurements reduce the risk of infection and no disposables are needed. However, more development is needed to improve the accuracy of trancutaneous measurements. Visual inspection is also common, but suffers from low accuracy.

    REPRESENTATIVE DEVICES

    MAKE
    MODEL
    PRICE*
    TECH
    STATUS
    NOTES

    Beckman

    AU480
    $140,000
    Chemistry analyzer
    Marketed

    Roche

    OMNI S
    $20,000
    Blood gas analyzer
    Marketed

    Philips

    BiliChek
    $6,000
    Transcutaneous
    Marketed

    Ginevri

    One Beam
    $4,000
    Microcapillary spectroscopy
    Marketed

    Ingram

    Icterometer
    $15
    Visual reference
    Marketed
    Visual color comparison

    * Prices are approximated. Actual pricing can, and will vary by marketplace and market conditions.

  • CHARACTERISTICS OF REPRESENTATIVE PRODUCT

    TECHNOLOGY CHARACTERISTICS

    OPERATIONAL PARAMETERS

    POTENTIAL OPPORTUNITIES FOR IMPROVEMENT

    SKILLS

    REQUIRED

    Intended end user
    Training required
    Time required per use
    Laboratory technician, nurse
    Hours
    Minutes

    Devices that do not require blood samples would reduce the level of skill needed, as safely drawing blood from newborns is a skilled task.

    ENVIRONMENT/ INFRASTRUCTURE

    Power required
    Waste collection
    Complementary technologies required
    Temperature and storage
    Maintenance
    Wall power, 50W
    Biohazard and sharps
    Clean collection, centrifuge, and heparinated capillary tubes
    Semi-annual calibration

    COST

    Device Cost (Approx)
    Cost/course (Approx)
    $3000-$5000
    <$5

    Given the relatively low component cost and device complexity, significant cost reduction may be possible.

    OTHER

    Portability
    Regulatory
    Efficacy
    2kg
    High correlation to HPLC

    Accuracy is reduced in populations with high carotenoid consumption. Implementation of a correction factor for carotenoids and other compounds with absorption spectra overlapping bilirubin would yield an incremental improvement.

    Additional devices required for impact: phototherapy device, eye and gonad covers.

Sources: WHO GMDN 47988 Bilirubinometer, 16166 Cutaneous bilirubinometer UMDNS 15109 Bilirubinometers Grohmann et al. 2006.Bilirubin Measurement for Neonates: Comparison of 9 Frequently Used Methods. Pediatrics;117;1174-1183. Ip et al. 2004.An Evidence-Based Review of Important Issues Concerning Neonatal Hyperbilirubinemia.; 114; e130-e153. Maisels. 2006. Neonatal Jaundice. Pediatr. Rev.27;443-454. Slusher et al. 2004. Transcutaneous Bilirubin Measurements and Serum Total Bilirubin Levels in Indigenous African Infants. Pediatrics;113;1636-1641.